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patients. PVI success and complication rates were similar between SHD and NHP. Con-
clusions: SHD does not affect outcomes of PVI for treatment of AF; its presence should
not preclude ICE/circular mapping guided PVI. * p < 0.05
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1129-209 Incidence of Cerebral Embolism After Cardioversion of 
Atrial Fibrillation: A Prospective and Serial Study Using 
Magnetic Resonance Imaging
Harald Schmidt, Peter Bernhardt, Christoph Hammerstingl, Stefan Illien, Christina 
Münsel, Torsten Sommer, Berndt Lüderitz, Heyder Omran, University of Bonn, Bonn, 
Germany
Background: The incidence of clinical apparent cerebral embolism in patients (pts) with
atrial fibrillation (AF) who underwent transesophageal echocardiographical (TEE) guided
cardioversion is approximately 1%. The incidence of clinically silent cerebral embolism
has not been analysed yet. The aims of this prospective studies were (1) to evaluate the
prognosis of cardioversion in pts with AF and (2) to assess the incidence of cerebral
embolism with MR-imaging (MRI).
Methods: The study group consisted of 102 pts with AF and TEE guided cardioversion.
To document the incidence of cerebral embolism all pts received oral anticoagulation
therapy (an INR > 2 was defined as effectively anticoagulated), neurological assessment
and cranial MRI including diffusion- weighted imaging within <24h before , <48h and 4
weeks after the procedure.
Results: 76 (75%) pts had sinus rhythm in the 4 weeks follow-up assessment. There
were no clinical apparent cerebral embolism. 2 (2%) pts had acute cerebral microembo-
lism in the MRI during the follow-up period. 59 (58%) pts were effectively anticoagulated
during the observation period. One patient with acute cerebral lesion in the MRI was not
effectively anticoagulated.
Conclusions: The incidence of clinically silent embolism after TEE guided cardioversion
in pts with AF under continued effective anticoagulation is low. The findings of this study
support the safety of the TEE guided approach to cardioversion in AF patients.
1129-210 Incidence of Cerebral Embolism in High-Risk Patients 
With Atrial Fibrillation
Harald Schmidt, Peter Bernhardt, Christoph Hammerstingl, Matthias Hackenbroch, 
Torsten Sommer, Berndt Lüderitz, Heyder Omran, University of Bonn, Bonn, Germany
Background: Patients (pts) with atrial fibrillation (AF) and spontaneous echo contrast
(SEC) have an increased stroke risk. The aims of this prospective study were (1) to eval-
uate the prognosis of pts with dense SEC and (2) to assess the incidence of cerebral
embolism with MR-imaging (MRI) under continued oral anticoagulation therapy.
Methods: The study group consisted of 64 pts with SEC and AF. 28 pts served as con-
trols. All pts received oral anticoagulation therapy during the follow-up period (an INR > 2
was defined as effectively anticoagulated). To document the incidence of cerebral embo-
lism all pts underwent the following examinations at admission and at 1, 3 and 12
months: transthoracic and transesophageal echocardiography, cranial MRI including dif-
fusion- weighted MRI, assessment of the anticoagulation level and neurological assess-
ment.
Results: 2 pts had clinically silent cerebral embolism at the index examination. Two
patients (3%) had cerebral embolism with neurological deficit during the follow-up period.
Four (6%) pts died during the observation period due to stroke. Additionally, 6 (9%) pts
had new appeared focal diffusion abnormalities in the MRI during the follow-up. 45 (70%)
pts were effectively anticoagulated, 15 (23%) pts were anticoagulated inadequately dur-
ing the 12 months. Pts with cerebral embolism had lower left atrial appendage peak
empty velocities (0.22 ± 0.14 vs. 0.38 ± 0.21; p<0.01) and denser SEC (2.8 ± 1.1 vs. 1.6
± 1.4; p<0.01) than pts without cerebral events.
Conclusions: Pts with AF and SEC have an increased risk of cerebral embolism despite
oral anticoagulation therapy. Low peak empty velocities of the left atrial appendage and
dense SEC are echocardiographic predictors for a cerebral event.
1129-211 Cardioversion for Chronic Atrial Fibrillation Is 
Associated With an Immediate Drop in Brain Natriuretic 
Peptide
Craig S. Vinch, Jason Rashkin, Giridhar Logsetty, Dennis A. Tighe, Jeffrey C. Hill, Theo 
E. Meyer, Lawrence S. Rosenthal, Gerard P. Aurigemma, University of Massachusetts 
Medical School, Worcester, MA, Brigham & Women's Hospital, Boston, MA
Background: Atrial fibrillation (AF) is often associated with heart failure (HF) symptoms,
even in patients with normal ejection fraction (EF). Since brain natriuretic peptide (BNP)
levels are elevated in HF, we hypothesized that BNP elevations in pts with AF would cor-
relate with HF symptoms, but would not fall immediately following cardioversion (CV),
since atrial mechanical function would not yet be restored. Accordingly, we studied BNP
in pts pre- and post CV, controlling for possible effects of conscious sedation (IVCS).
Methods: We enrolled 50 consecutive pts (39 male, 11 female, age 62 ± 14) undergoing
CV, with mean EF 54% ± 12: 38 pts had EF >50%; 17 consecutive pts (12 male, age 61
± 16 years) receiving IVCS for non-AF related TEE served as controls. Results:Pre-CV
BNP exceeded 100 pg/ml in 36/50 (72%) pts, and tended to correlate with HF symptoms
(p=0.06). BNP fell immediately following CV in 36/49 (73%). By contrast, BNP rose in
association with IVCS in 13/16 (81%) controls. Summary/Conclusions: BNP (1) is ele-
vated in chronic AF, despite normal EF and (2)correlates with number of HF symptoms,
likely reflecting elevated filling pressures and/or neurohumoral activation; surprisingly (3)
BNP falls in most pts immediately following CV, but this fall (4) does not appear to be due
to IVCS. Given the rapidity of the fall in BNP, we speculate that CV-associated drop in
BNP likely reflects the salutary effects of rhythm uniformity rather than reestablishment of
atrial kick. 
1129-212 Endothelial, Coagulation, and Platelet Function in Atrial 
Fibrillation: Effect of Direct Current Cardioversion
Fraser Witherow, Neil Grubb, Christopher Ludlam, Keith A. Fox, Andrew D. Flapan, 
Cardiovascular Research, Edinburgh, United Kingdom
Background. Atrial fibrillation (AF) is the most common human arrhythmia with a preva-
lence in the elderly population of up to 15%. It results in breathlessness, palpitations and
systemic embolisation due to a procoagulant state. Recent studies of AF have suggested
that rate control with anticoagulation may have a superior outcome compared to rhythm
control. The aim of this study was to assess the effect of D.C. cardioversion on markers of
coagulation and platelet activity and endothelial function in patients with AF on warfarin
therapy.
Methods Sixty patients undergoing elective D.C cardioversion for non-valvular atrial
fibrillation were recruited to the study. All patients were taking warfarin aiming for an INR
of 2-3. D.C cardioversion was performed under general anaesthetic following our local
protocol. Peripheral venous blood was sampled through a 16G needle prior to cardiover-
sion and at 2,4,6 and 10 weeks post cardioversion provided they remained in sinus
rhythm (SR). Warfarin was discontinued 6 weeks after cardioversion. The samples were
assayed for INR, prothrombin fragment 1+2, d-dimer, beta thromboglobulin, and von Will-
iebrand factor.
Results. Nine patients failed to cardiovert to sinus rhythm, and 8 people withdrew from
the study. Median age was 65 (39-77) years. Mean INR was 2.4±0.3. At 2 weeks, 20
patients remained in SR and 23 had reverted to AF. Compared to baseline, D.C. cardio-
version produced no significant change in prothrombin fragment 1+2 (p=0.1), d-dimer
(p=0.3), beta thromboglobulin (p=0.3), or von Williebrand factor (p=0.6). No significant
change in coagulation or platelet activity was seen at 4 weeks (n=15) or 6 weeks (n=18),
compared to baseline. At 10 weeks, once warfarin was discontinued, only prothrombin
fragment 1+2 levels were higher than at baseline (p=0.009).
NHP SHD EF<40% VD CVS
N 194 183 94 102 26
Age, y 54±12 56±11 54±1 58±10* 61±11*
Left atrial size, cm 4.4±2.4 4.7±1.8 4.7±0.6 4.7±2.0 4.9±0.3*
NYHA 1 1.4 1.6 1.4 1.5
Fluoro time, min 83±26 87±20 89±20* 85±20 87±22
Procedure time, h 4±1 4±1 5±1* 4±1 4±1
Neurologic Event 1 3 3 1 0
Tamponade 4 0 0 0 0
Access Site Hematoma 1 1 0 1 0
Severe PV Stenosis 2 2 1 1 0
Recurrence 31 27 25 17 2
2nd PVI 27 21 21 12 1
Overall Success, % 98 95 95 93 96
Follow-up, months 18±7 12±6 13±5 11±5 11±6
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Conclusion. Achieving rhythm control with D.C. cardioversion does not improve coagula-
tion or platelet markers in patients with AF. This study may in part explain why rate control
with anticoagulation seems superior to rhythm control in patients with AF.
1129-213 Which Patients With Atrial Fibrillation or Atrial Flutter 
Benefit From Electrical Cardioversion?
Ahmad A. Elesber, A. Gabriela Rosales, Joseph Maalouf, Nasser Ammash, David 
Hodge, Stephen C. Hammill, Paul A. Friedman, Mayo Clinic, Rochester, MN
Background: Optimal management of new onset atrial fibrillation (Afib) or flutter (Aflu) is
not known. We sought to determine the recurrence rate of atrial arrhythmia post electrical
cardioversion (DCCV) of new onset Afib and Aflu.
Methods: A cohort of 244 patients (pts) with documented Afib (119 with new onset Afib)
and 79 pts with Aflu (52 with new onset Aflu) were followed after DCCV for recurrence.
Post-surgical pts with Afib or Aflu were excluded. Cox proportional hazards models were
used to construct multivariate models.
Results: The mean age was 71.1±12.4 years with 69% being males, 30% had coronary
artery disease, 19% had congestive heart failure and 68% had hypertension. The mean
follow up was 159.5±171.2 days. Pts with recurrent Afib (57.6%) or recurrent Aflu (63%)
were more likely to be on antiarrhythmic medications than pts with new onset Afib
(19.3%) or new onset Aflu (3.9%), p<0.05. In a multivariate model, pts with a bigger right
atrial size (p=0.02) or mitral valve disease (p<0.01) were more likely to have recurrence
of atrial arrhythmia. Use of antiarrhythmic medications had no effect on recurrence. Pts
with new onset Aflu were less likely to recur after DCCV than pts with new onset Afib or
either recurrent Aflu or Afib, p<0.001 (see figure).
Conclusion: DCCV for pts with new onset Aflu is a reasonable strategy with 65% of pts
maintaining sinus rhythm at 1.5 years of follow-up. Only 20% of pts with Afib or recurrent
Aflu remained in sinus rhythm at 1.5 years of follow-up.
1129-214 Atrial Fibrillation and Heart Failure: Preserved Systolic 
Function Does Not Predict a Benign Prognosis
Ratika Parkash, F. Michael Toca, William H. Maisel, William G. Stevenson, Brigham and 
Women's Hospital, Boston, MA
Background: The prognostic significance of preserved systolic function in heart failure
(HF) and atrial fibrillation (AF) is controversial.
Methods:To determine the impact of ventricular function (EF) on mortality associated with
AF and HF data were reviewed from consecutive patients presenting to the emergency
department at Brigham and Women's Hospital from January 1998 to December 2001
who had both AF and HF and a measure of EF. Vital status was determined from the
Social Security Death Index. Survival analysis was performed.
Results: A total of 1759 patients met entry criteria (mean age 73+/-12 yrs, 44% women).
EF was preserved (>50%) in 42%. No difference in median survival was found amongst
patients with an EF > 50% (3.30 yrs, 95% CI (2.70,3.79)) compared to those with an EF
</= 50% (3.19 yrs, 95% CI (2.73,3.67))(p=0.70), even after adjustment for age, gender,
creatinine (Cr) and QRS duration. In multivariable analysis older age, male gender and
increased Cr were predictive of increased mortality.
Conclusion: Patients with atrial fibrillation, heart failure and preserved EF have similar
mortality to those with depressed EF. Further study is needed to assess the impact of
therapies and clarify the reasons for poor prognosis. 
1129-215 Energy Selection for Elective External Direct Current 
Cardioversion: A Randomized Comparison of High 
Initial Energy and Conventional Step-Up Protocol
Lana Boodhoo, George Bordoli, Andrew Mitchell, Nikhil Patel, Neil Sulke, Eastbourne 
General Hospital, Eastbourne, United Kingdom
BACKGROUND: Current guidelines recommend a step-up energy protocol for the car-
dioversion of atrial arrhythmias. The aim of this study was to compare such a protocol
with a protocol involving an initial high energy shock.
METHODS: This prospective single-blind study enrolled 261 consecutive patients (mean
age 71 ± 10 years, 62% male) referred for elective transthoracic cardioversion of persis-
tent atrial fibrillation (AF). Patients were randomised to either protocol A: (1) 200J
anteroapical (AA), (2) 360J AA, (3) 360J anteroposterior (AP) or
protocol (B): (1) 360J AA (2) 360J AP and (3) 360J posteroanterior (PA).
All procedures were performed under deep sedation with intravenous diazepam.
RESULTS: Both procedures resulted in similar success rates after the maximum of 3
shocks (A 82%, B 87%, p=0.3), however there was a highly significant increase in 1st
shock success for protocol B, 68%, versus 41% for protocol A, p<0.0001. Protocol B
resulted in significantly fewer shocks to achieve sinus rhythm as compared to protocol A
(1.3 ± 0.6 versus 1.6 ± 0.7, p=0.0002). There were no differences in cumulative energy
used (group A, 473 ± 286J, versus group B, 436 ± 273J, p=0.24) or sedation require-
ments (group A, 22 ± 9 mg, group B, 22 ± 9 mg, p=0.7).
CONCLUSION: High initial energy cardioversion for atrial fibrillation increased 1st shock
success and decreased shock frequency but resulted in similar overall conversion rates,
cumulative energy and use of sedation compared with conventional step-up protocol.
Reversal of polarity should be considered in patients who fail initial shocks.
1129-216 How Does Age Influence the Prescribing of 
Antithrombotic Therapy for Ambulatory Patients With 
Permanent Atrial Fibrillation?
Alain Leizorovicz, Maxime Guenoun, Jean Yves Le Heuzey, Claude Jeandel, Patrick 
Mismetti, Ariel Cohen, The FALSTAF Study Group, School of Medicine Laennec, Lyon, 
France
Background: . Prescription of antitrhombotics in Atrilal Fibrillation (AF) patients (pts) and
its determinants in elderly patients are not well known. We undertook a survey in ambula-
tory AF patients in France.
Methods: We prospectively surveyed consecutive outpatients with documented perma-
nent AF with or without valvular disease, excluding those with valvular prostheses. Cardi-
ologists or general practitioners were selected at random
Results: 5893 pts were included by 188 cardiologists (2367 pts) and 582 general practi-
tioners (3526 pts). Their mean age was 75.8 years, 58% were men, .31.7% had Valvular
disease.
Overall, 95.5% of pts were being prescribed an antithrombotic drug, including vitamin K
antagonists (VKA) in 76.4% of pts and aspirin in 16.6% .
Higher age was a strong predictive factor for lower prescribing of antithrombotic ther-
apy.even after multivariate adjustment for other factors with a significant negative influ-
ence on prescribing, such as poor autonomy, history of severe hemorrhage and
potentially haemorrhagic diseases.
Above 80 years, 7.4% of pts were not receiving antithrombotic prophylaxis.
Among pts receiving an antithrombotic therapy, the use of VKA decreased sharply after
75 years in favor of aspirin (figure)
Conclusions: In our study, a majority of ambulatory patients with permanent AF were
